The stock has outperformed the sector but lagged the S&P ... disease has progressed on or after platinum-based chemotherapy.

In the most recent trading session, Gilead Sciences (GILD) closed at $91.09, indicating a +0.44% shift from the previous trading day.

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, with a market cap of $115.3 billion, is a global ...

Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,075.53 today based on a ...

Value stocks -- a market segment that includes high-yield stocks -- outperformed growth stocks in 2022. That's a recent rarity, as for more than a decade, the performance record favored growth ...

Shares of Assembly Biosciences (NASDAQ:ASMB) traded higher on Thursday after Gilead Sciences (NASDAQ:GILD) agreed to increase ...

Oppenheimer previewed the upcoming year for the firm’s Biotechnology coverage and said the firm’s top ideas for 2025 are Capricor (CAPR), ...

Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential ...

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $91.86 which represents a decrease of $-0.52 or -0.56% from the prior close of $92.38. The stock opened at $91.66 and touched a low ...

Therefore, the Zacks rating upgrade for Gilead basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. The change in ...

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. For the current quarter, Gilead is expected to ...